SAN DIEGO, Aug. 8, 2017 /PRNewswire/ -- Sirenas, LLC, a leader in the application of deep data mining approaches to the discovery of new classes of therapeutics from the global microbiome, today announced appointments to its board: Mary Haak-Frendscho, Ph.D., venture partner at Versant Ventures and CEO of Blueline Bioscience, and Bob More, managing director of Alta Partners.
"Mary and Bob bring deep knowledge of the biotechnology industry to our board, which has already been tremendously helpful in steering our business and advising on strategies to pursue," said Eduardo Esquenazi, Ph.D., founder of Sirenas. "As we continue to establish industry partnerships and advance our pipeline, I'm confident that their insights will maximize value."
Mary Haak-Frendscho built her career in biotechnology, and currently serves as a venture partner at Versant Ventures and as CEO and board member of Blueline Bioscience, the Canadian discovery engine for Versant. She also serves on the board of Northern Biologics. Dr. Haak-Frendscho brings over 25 years of scientific and business leadership to the company from prior roles including founding president, CSO and board member of Takeda San Francisco.
Bob More brings over 20 years of successful investment experience at leading life science venture capital firms. Currently, he is managing director at Alta Partners and serves on the boards of One Revolution and The Foundation for Innovative New Diagnostics (FIND). Previously he was with Frazier Healthcare Partners, Domain Associates, was a senior advisor of venture investing at the Bill & Melinda Gates Foundation and served on multiple boards.
"The team at Sirenas has built a high-value, transformational big data platform that rapidly mines information from the millions of compounds they have isolated from global microbiome collections," said More. "This resource is allowing Sirenas to uncover therapeutic leads from a previously hidden, rich pool of privileged chemistry that can be leveraged to help tackle the greatest unmet disease needs."
Sirenas aims to translate the high-value chemical language of the global microbiome – the microbial life existing in diverse ecosystems all over the world – into groundbreaking new discoveries for the most pressing unmet medical needs. Sirenas has uniquely combined this highly evolved chemical diversity with its Atlantis™ proprietary deep data mining technology and next-generation synthetic chemistry to create a fully integrated, rapid and validated approach to drug discovery. Sirenas drug discovery programs are focused on eliminating cancer through targeted therapy and immune modulation. Sirenas is headquartered in San Diego and has a presence at JLABS San Diego. For more information about Sirenas, please visit www.SirenasMD.com.
SOURCE Sirenas, LLC